Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of a single-dose Covid-19 vaccine.
hVIVO, part of Open Orphan, will conduct the vaccine trial for Codagenix at its quarantine facility in London.
Open Orphan said that 48 healthy young adult volunteers will take part in the trial.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).